International Journal of Health Policy and Management

International Journal of Health Policy and Management

Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?

Document Type : Letter to Editor

Authors
Yurie Kobashi 1, 2
Makoto Watanabe 3
Hideaki Kimura 3
Asaka Higuchi 1
Akihiko Ozaki 1, 4
1 Medical Governance Research Institute, Tokyo, Japan
2 Department of Anesthesia, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan
3 Waseda Chronicle, Tokyo, Japan
4 Department of Breast Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan
10.15171/ijhpm.2019.60
Keywords
Pharmaceutical Payments
Database
Research Systems
Collaboration
Subjects

Dear Editor,

Pharmaceutical industry (Pharma) funding plays a pivotal role in medical progress but has resulted in the extensive commercialization of clinical and academic research.1 Profit-driven interest from Pharma has been demonstrated to have a negative impact on the integrity and objectivity of science, research publications and patient management.2,3... (Read more...)

  1. Lemmens T. Leopards in the temple: restoring scientific integrity to the commercialized research scene. J Law Med Ethics. 2004;32:641-657. doi:10.1111/j.1748-720X.2004.tb01969.x
  2. McNeill PM, Kerridge IH, Henry DA, et al. Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia. Intern Med J. 2006;36:571-578. doi:10.1111/j.1445-5994.2006.01151.x
  3. Rosenbaum L. Conflicts of interest: part 1: Reconnecting the dots–reinterpreting industry-physician relations. N Engl J Med. 2015;372:1860-1864. doi:10.1056/NEJMms1502493
  4. Fickweiler F, Fickweiler W, Urbach E. Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians’ attitudes and prescribing habits: a systematic review. BMJ Open. 2017;7(9):e016408. doi:10.1136/bmjopen-2017-016408
  5. Nissen SE.Conflicts of interest and professional medical associations progress and remaining challenges. JAMA. 2017;317:1737-1738. doi:10.1001/jama.2017.2516
  6. Sawano T, Ozaki A, Saito H, Shimada Y, Tanimoto T. Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan. JAMA Netw Open. 2019;2(5):e193817. doi:10.1001/jamanetworkopen.2019.3817
  7. Saito H, Ozaki A, Kobayashi Y, Sawano T, Tanimoto T. Pharmaceutical company payments to executive board members of professional medical associations in Japan. JAMA Intern Med. 2019;179(4):578-580. doi:10.1001/jamainternmed.2018.7283
  8. Saito H, Ozaki A, Sawano T, Shimada Y, Tanimoto T. Evaluation of pharmaceutical company payments and conflict of interest disclosures among oncology clinical practice guideline authors in Japan. JAMA Netw Open. 2019;2(4):e192834. doi:10.1001/jamanetworkopen.2019.2834
International Journal of Health Policy and Management
Volume 8, Issue 10
October 2019
Pages 627-628

  • Received Date 17 April 2019
  • Revised Date 12 July 2019
  • Accepted Date 13 July 2019
  • First Published Date 01 October 2019
  • Published Date 01 October 2019